Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience

Basit Öğe Kaydı
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorSaricanbaz, Irem
dc.contributor.authorBora, Huseyin
dc.contributor.authorKarahacioglu, Eray
dc.contributor.authorErkal, Eda Yirmibesoglu
dc.date.accessioned2024-02-23T14:37:53Z
dc.date.available2024-02-23T14:37:53Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjectives: There is no consensus regarding the management of Stage 1 seminomas following inguinal orchiectomy. In this study, we evaluated the treatment results and treatment-related toxicity for patients with Stage 1 seminomas treated with adjuvant radiotherapy (RT) at a single institution. Methods: Sixty-five patients who underwent adjuvant RT following orchiectomy for Stage 1 seminomas between January 1996 and December 2007 were retrospectively reviewed. The age, tumor location, histopathological type, stage, tumor size, RT field, and radiation dose were recorded for all patients. Results: The patients' ages ranged from 17 to 61 years (median, 37 years). Sixty-three patients (97%) were diagnosed with classical seminoma and the remaining two patients (3%) had spermatocytic seminoma. After orchiectomy, 37 patients (57%) received para-aortic RT and 28 patients (43%) received dog-leg field RT. RT was applied with 1.8u2 Gy/day fractionation and the median RT dose was 26 Gy (range, 20u38). Follow-up ranged from 0.3 to 18 years (median, 9.5 years). Local control had been achieved in all patients and all of them were alive with no evidence of disease. Fifty-one patients (77%) had at least 5 years of follow-up and 27 patients (41%) had at least 10 years of follow-up. Overall survival at 10 years was 100%. Conclusion: Although retrospective in nature, this single-institutional study provides useful information about the outcomes and toxicities associated with adjuvant RT in patients with Stage 1 seminomas reporting excellent disease control and survival rates at the expense of acceptable toxicity.en_US
dc.identifier.doi10.4103/jcrt.JCRT_916_16
dc.identifier.endpageS90en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.pmid30900627en_US
dc.identifier.scopus2-s2.0-85063504708en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageS87en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_916_16
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16260
dc.identifier.volume15en_US
dc.identifier.wosWOS:000462681000015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDose And Fielden_US
dc.subjectLate Complicationen_US
dc.subjectRadiotherapyen_US
dc.subjectSecondary Malignancyen_US
dc.subjectTesticular Seminomaen_US
dc.titleAdjuvant radiotherapy for Stage I seminoma: A Single-institutional experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu